Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
MIPS Value Pathway (MVP) for Urology – Optimal Care for Patients with Urologic Conditions
What This Means for AQUA Participants
MVPs streamline MIPS reporting by aligning measures to urology care—reducing administrative burden while improving benchmarking across similar practices.
The urology MVP includes:
- 14 Quality Measures across oncology and general urology (e.g., prostate cancer, BPH, urinary incontinence, stone care)
- 17 Improvement Activities focused on care coordination, telehealth, and health equity
- 3 Cost Measures, including prostate cancer (new in 2025) and Medicare Spending per Beneficiary
Why It Matters
As a CMS-approved QCDR, the AQUA Registry is well-positioned to support MVP adoption. Through specialty-specific measures, benchmarking insights, and reporting guidance, AQUA helps practices:
- Align more efficiently with MVP requirements
- Use actionable urology data to drive performance improvement
- Prepare for future MVP participation
With voluntary reporting underway, now is the time to assess readiness and make the most of your AQUA participation.
Dates to Remember
April 1–November 30, 2026
- 2026 MVP registration window
October 3, 2026
- The last day to start the 180-day performance period for the promoting interoperability performance category
December 31, 2026
- Application deadline for the MIPS Promoting Interoperability Headship Execption
January 2, 2027–March 31, 2027
- Data submission period for 2026 MIPS reporting
advertisement
advertisement